PT - JOURNAL ARTICLE ED - , TI - â–¼Gemcitabine for lung cancer AID - 10.1136/dtb.1996.34971 DP - 1996 Sep 01 TA - Drug and Therapeutics Bulletin PG - 71--72 VI - 34 IP - 9 4099 - http://dtb.bmj.com/content/34/9/71.short 4100 - http://dtb.bmj.com/content/34/9/71.full SO - Drug Ther Bull1996 Sep 01; 34 AB - Relevant BNF section: 8.1.3The prognosis for most patients with lung cancer is poor. About 75% will have tumours of non-small-cell lung cancer (NSCLC) type and, at diagnosis, 4 out of 5 patients with NSCLC have either locally advanced or metastatic disease. Despite treatment, fewer than 1 in 10 of these people will be alive 5 years later. Gemcitabine (Gemzar - Lilly) has recently been licensed for the palliative treatment of adults with such late-stage cancers. It is promoted as a "new option in the management of NSCLC" with "no trade off between tumour remission and toxicity". What advantages does gemcitabine offer?